Citryll

Over Citryll

Citryll has translated a deep understanding of the extracellular trap (ET) pathway to therapeutically address its central role in a broad range of immune-mediated inflammatory diseases (IMIDs). With a unique dual mode of action, the company’s lead antibody, CIT-013, has reached the clinic by demonstrating a precise and powerful ability to control ETs and ETosis. Citryll is initially developing CIT-013 as a novel drug for rheumatoid arthritis and hidradenitis suppurativa, which may serve as enabling indications for a wide spectrum of IMIDs.

Trefwoorden

• Antibody Development
• Hidradenitis Suppurativa
• Immunology
• Inflammatory Diseases
• Neutrophil Extracellular Traps
• Rheumatoid Arthritis
• Therapeutics Development

Adres

• Hoofdkantoor

  5349AE OssNoord-Brabant, Nederland

Team per functiegebied

Gebaseerd op 35 openbare functieprofielen, stand van 2 september 2026.

• Research / R&D17
• Executive / C-Suite5
• Consulting / Advisory2
• Healthcare / Medical2
• Operations2
• Other / Unclassifiable2
• Data / Analytics / Science1
• Finance / Accounting1
• Founder / Owner1
• IT / Infrastructure / Security1
• Marketing1